GlassScriptPhysician profile
Denise O'Neil
NPI 1184164865
$3,375.70
in general payments reported to CMS, 2019-2025
16 companies · $1,324 in 2025
The $1,324 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $483 · 2022: $467 · 2023: $577 · 2024: $525 · 2025: $1,324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $720.63 | 2021-2023 | |
| Corium, LLC | $463.59 | 2023-2025 | Azstarys |
| Astrazeneca Pharmaceuticals LP | $419.95 | 2022-2025 | Airsupra, Fasenra, Wainua |
| Collegium Pharmaceutical, INC. | $262.50 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $206.69 | 2023-2024 | Jornay Pm |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $193.39 | 2024-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $171.08 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $155.23 | 2024-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $125.00 | 2025 | Fanapt |
| Regeneron Healthcare Solutions, INC. | $124.99 | 2025 | Dupixent |
| Lundbeck LLC | $123.32 | 2024-2025 | Rexulti |
| Vertex Pharmaceuticals Incorporated | $119.77 | 2025 | |
| Akcea Therapeutics, INC. | $112.11 | 2021 | |
| Horizon Therapeutics Plc | $99.84 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.95 | 2025 | Trintellix |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $32.66 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise O'Neil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.